What does low luteinizing hormone and follicle‑stimulating hormone, very low testosterone, normal anti‑Müllerian hormone, unilateral cryptorchidism, and a small penis indicate in a 9‑year‑old boy, and what is the recommended management?

Hypogonadotropic Hypogonadism (Central Hypogonadism)

This 9-year-old boy has hypogonadotropic hypogonadism (central hypogonadism), indicated by the combination of very low LH (<0.3 U/L), low FSH (0.3 U/L), undetectable testosterone (<0.09 nmol/L), micropenis, cryptorchidism, and crucially, normal anti-Müllerian hormone (45.90 µg/L), which confirms the presence of functional testicular tissue. The normal AMH excludes primary testicular failure and points directly to a hypothalamic-pituitary defect 1, 2.

Diagnostic Interpretation

The hormonal pattern is diagnostic:

• Low LH and FSH with low testosterone = central (hypogonadotropic) hypogonadism, not primary testicular failure 3, 1
• Normal AMH (45.90 µg/L) = functioning Sertoli cells are present, confirming testicular tissue exists and responds to whatever minimal FSH stimulation is present 4, 1, 5
• Micropenis + unilateral cryptorchidism = classic presentation of congenital hypogonadotropic hypogonadism in prepubertal boys 6, 2

In a 9-year-old boy, these findings are particularly significant because LH and testosterone are physiologically low during mid-childhood, making diagnosis challenging. However, FSH and AMH should be measurable and normal during this age 1. The combination of low FSH with normal AMH indicates the testes can function but lack adequate gonadotropin stimulation 1, 2.

Clinical Significance

This represents congenital hypogonadotropic hypogonadism (CHH), which may be:

• Kallmann syndrome (if anosmia present - check sense of smell)
• Normosmic hypogonadotropic hypogonadism (if smell is normal)
• Part of multiple pituitary hormone deficiencies (check for other deficiencies, growth patterns, neonatal hypoglycemia history)
• Associated with genetic syndromes like CHARGE 6

The normal AMH is particularly reassuring as it indicates preserved Sertoli cell function and suggests the testes retain capacity to respond to treatment 4, 1, 5.

Immediate Management Algorithm

1. Urgent Endocrinology Referral

Refer immediately to pediatric endocrinology for comprehensive evaluation 3. This is not a condition for primary care management alone.

2. Additional Diagnostic Workup Required

Hormonal evaluation:

• Repeat early morning LH, FSH, testosterone to confirm (though at age 9, testosterone will remain low) 3
• Measure serum prolactin - if elevated, suggests pituitary adenoma 3
• Check other pituitary hormones: IGF-1, free T4, TSH, cortisol, ACTH to exclude multiple pituitary hormone deficiencies 6
• Consider GnRH stimulation test to confirm impaired gonadotropin response (though diagnosis is already clear from basal values) 1

Imaging:

• Pituitary MRI is mandatory with testosterone <150 ng/dL (~0.52 nmol/L) and low/normal LH to identify pituitary masses or structural abnormalities 3
• Olfactory bulb imaging if Kallmann syndrome suspected 6

Genetic testing:

• Gene panel sequencing for CHH-associated genes (FGFR1, ANOS1, CHD7, PROKR2) - pathogenic variants found in 61-84.6% of cases 6, 2
• Karyotype if additional features suggest chromosomal abnormality

Assess for associated anomalies:

• Hearing assessment (10% have hearing impairment in Kallmann syndrome) 6
• Renal ultrasound (renal anomalies associated with some CHH genes)
• Cardiac evaluation if syndromic features present 6
• Formal olfactory testing 6

3. Cryptorchidism Management

The cryptorchid testis requires surgical correction regardless of the underlying hypogonadism [@2-7@]. According to AUA guidelines, orchiopexy should have been performed by 6-18 months of age 7. At age 9, this is significantly delayed but still indicated to:

• Reduce (but not eliminate) testicular cancer risk 7
• Preserve remaining fertility potential 7
• Facilitate future testicular examination 7

Refer to pediatric urology for orchiopexy - do not delay further [@2-7@]. Imaging is not needed before surgical referral 7. The normal AMH confirms testicular tissue is present 4, 5.

4. Hormone Replacement Timing

Do NOT start testosterone replacement immediately. The approach depends on goals:

For pubertal induction (starting around age 11-14):

• Begin low-dose testosterone at bone age 11-12 years or chronological age 14 years, whichever comes first 6
• Options: oral testosterone, intramuscular testosterone, or transdermal 6
• Gradual dose escalation over 2-3 years to mimic normal puberty

For fertility preservation:

• Consider gonadotropin therapy (hCG ± FSH) instead of testosterone if future fertility is a priority 3, 2
• Testosterone suppresses spermatogenesis; gonadotropins stimulate it 3

Current management (age 9):

• Monitor growth velocity and bone age
• Optimize nutrition and general health
• Psychological support for patient and family
• Plan for timely pubertal induction

Critical Pitfalls to Avoid

1. Do not assume this is isolated cryptorchidism - the micropenis and hormonal profile indicate systemic hypogonadism requiring endocrine management 2

2. Do not use hormonal therapy (hCG/GnRH) to treat the cryptorchidism - AUA guidelines explicitly state hormonal therapy is not recommended for cryptorchidism treatment; orchiopexy is required [@2-7@]

3. Do not delay pituitary imaging - with these hormone levels, MRI is mandatory to exclude pituitary pathology 3

4. Do not start testosterone without endocrine consultation - timing and choice of therapy (testosterone vs. gonadotropins) depends on multiple factors including fertility goals 3, 6

5. Do not forget fertility counseling - this patient will likely have impaired fertility from both the hypogonadism and the cryptorchidism 7, 2. Early orchiopexy and appropriate hormone therapy can optimize but not guarantee fertility potential.

Long-term Monitoring

• Testicular cancer surveillance: Teach testicular self-examination after puberty; formerly cryptorchid testes have increased malignancy risk even after orchiopexy 7
• Fertility assessment: Semen analysis in late adolescence/early adulthood 7
• Bone density monitoring: Hypogonadism impairs bone mineralization; early treatment improves outcomes 1
• Growth monitoring: Ensure appropriate pubertal growth spurt with hormone replacement 1
• Psychosocial support: Delayed puberty and fertility concerns require ongoing counseling 7

The combination of normal AMH with profoundly low gonadotropins makes this diagnosis straightforward, but the implications for lifelong management are substantial 1, 2.